LONDON and NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, today announces the activation of the first…Read More
OKYO Pharma Announces Activation of First Clinical Trial Site in the US for the Phase 2 Trial Evaluating OK101 for the Treatment of Dry Eye Disease
